Related Experiment Video
Updated: Apr 16, 2026
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency
Chuan Liu1, Hongyu Ding2, Xiaoxi Li2
1Key Laboratory of Systems Biology, State Key Laboratory of Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China Department of Oncology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Abstract:
Genotoxic drugs constitute a major treatment modality for human cancers; however, cancer cells' intrinsic DNA repair capability often increases the threshold of lethality and renders these drugs ineffective. The emerging roles of HDACs in DNA repair provide new opportunities for improving traditional genotoxic drugs. Here, we report the development and characterization of CY190602, a novel bendamustine-derived drug with significantly enhanced anticancer potency. We show that CY190602's enhanced potency can be attributed to its newly gained ability to inhibit HDACs. Using this novel DNA/HDAC dual-targeting drug as a tool, we further explored HDAC's role in DNA repair. We found that HDAC activities are essential for the expression of several genes involved in DNA synthesis and repair, including TYMS, Tip60, CBP, EP300, and MSL1. Importantly, CY190602, the first-in-class example of such DNA/HDAC dual-targeting drugs, exhibited significantly enhanced anticancer activity in vitro and in vivo. These findings provide rationales for incorporating HDAC inhibitory moieties into genotoxic drugs, so as to overcome the repair capacity of cancer cells. Systematic development of similar DNA/HDAC dual-targeting drugs may represent a novel opportunity for improving cancer therapy.
Insights
A new drug, CY190602, combines genotoxic effects with HDAC inhibition to enhance cancer treatment. This dual-action approach overcomes cancer cell DNA repair, improving drug efficacy in preclinical studies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Genotoxic drugs are vital cancer treatments, but cancer cells' DNA repair mechanisms limit their effectiveness.
- Histone deacetylases (HDACs) play emerging roles in DNA repair, presenting therapeutic targets.
- Developing strategies to overcome cancer cell resistance is crucial for improving treatment outcomes.
Purpose of the Study:
- To develop and characterize CY190602, a novel bendamustine derivative with enhanced anticancer potency.
- To investigate the role of HDACs in DNA repair using CY190602 as a tool.
- To explore the potential of dual-targeting DNA/HDAC drugs in cancer therapy.
Main Methods:
- Synthesis and characterization of CY190602, a novel bendamustine-derived compound.
- In vitro and in vivo evaluation of CY190602's anticancer activity.
- Assessment of HDAC inhibition and its impact on DNA repair gene expression (e.g., TYMS, Tip60, CBP, EP300, MSL1).
Main Results:
- CY190602 demonstrated significantly enhanced anticancer potency compared to traditional genotoxic drugs.
- The enhanced efficacy of CY190602 is attributed to its dual action: DNA damage and HDAC inhibition.
- HDAC activity was found to be essential for the expression of key DNA synthesis and repair genes.
Conclusions:
- CY190602 is the first-in-class DNA/HDAC dual-targeting drug with potent in vitro and in vivo anticancer activity.
- Inhibiting HDACs can overcome cancer cell DNA repair capacity, enhancing genotoxic drug effectiveness.
- Developing similar dual-targeting drugs offers a promising new avenue for improving cancer therapeutics.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:34Inhibition of Cdk Activity